The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 6 May 2026•Updated 6 May 2026•

1 min read

Huron Reports 12% Q1 Revenue Growth and Reaffirms Full-Year 2026 Outlook

Key Facts

1Huron's revenues before reimbursable expenses increased 12.1% to $443.7 million in the first quarter of 2026.

2Adjusted EBITDA rose by 21.9% to $50.6 million during the quarter.

28 days ago

Version History

Version 128 days ago

What changed: The story was updated to incorporate details from the earnings calls of both Huron and Rigel Pharmaceuticals, providing additional operational context.

Huron Consulting Group reported strong Q1 2026 results, with revenues rising 12.1% to $443.7 million, driven by robust performance in Healthcare and Education. During its recent earnings call to discuss operational details, the company highlighted an adjusted EBITDA of $50.6 million, a 21.9% increase. Following these results, Huron reaffirmed its full-year guidance, projecting revenues between $1.78 billion and $1.86 billion. Additionally, the release of Rigel Pharmaceuticals' (RIGL) Q1 earnings transcript provides further context for the broader healthcare consulting landscape. These updates underscore Huron's operational resilience and its commitment to shareholder value through ongoing share repurchases. The company remains well-positioned to maintain consistent growth within the consulting services sector.